Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy
The effects of parenteral and parenteral plus oral estrogen therapy on the serum levels of sex hormone binding globulin (SHBG), pregnancy‐associated (α‐PAG), growth hormone (GH), and somatomedin C (SmC) were studied in 26 patients with prostatic cancer. Intramuscular polyestradiol phosphate treatmen...
Gespeichert in:
| Veröffentlicht in: | The Prostate 1987, Vol.10 (4), p.333-338 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 338 |
|---|---|
| container_issue | 4 |
| container_start_page | 333 |
| container_title | The Prostate |
| container_volume | 10 |
| creator | Stege, Reinhard Fröhlander, Nils Carlström, Kjell Pousette, Åke Von Schoultz, Bo |
| description | The effects of parenteral and parenteral plus oral estrogen therapy on the serum levels of sex hormone binding globulin (SHBG), pregnancy‐associated (α‐PAG), growth hormone (GH), and somatomedin C (SmC) were studied in 26 patients with prostatic cancer. Intramuscular polyestradiol phosphate treatment, yielding a mean serum level of estradiol‐17β of 1,446 pM and a mean testosterone level of 4.5 nM, had no significant effects on α‐PAG, GH, and SmC and increased SHBG levels only marginally. Combined treatment with intramuscular polyestradiol phosphate and oral ethinyl estradiol greatly increased SHBG and α‐PAG levels and caused elevated GH and decreased SmC levels. The route of estrogen administration is probably of major importance for the hormonal effects on hepatic activity as reflected by SHBG and α2‐PAG levels. Bypassing the portal circulation might be advantageous with respect to liver‐related side effects of estrogen therapy. GH and SmC might act as mediators of estrogen effects on the human liver. |
| doi_str_mv | 10.1002/pros.2990100407 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77601388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77601388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4117-ee3839393fc8aacad64f7c5db0e7a41354c427c34961268f07969d7a39d31c583</originalsourceid><addsrcrecordid>eNqFUEFvFCEYJUZTt9WzJxMOxlOnhYEZBnsya201jTWuxsQLocxHF52BFVjrHv3nMu5mjSdDAnz53nvf-x5CTyg5oYTUp6sY0kktJSkVJ-IemlEiRVWK5j6akVqQilMmHqLDlL6SCUXqA3RQc14KPkO_FhlicH2VwCeX3Q_ARTKD8-kY38Zwl5d4GeIYPGDte5zCqHMYoXcez3G5JgNZZ2ew0d5AfIHPrQWTEw4Wr3QEXwbo4Q85TB9IOYZb8DgvS2O1eYQeWD0keLx7j9Cn1-cf55fV1fXFm_nLq8pwSkUFwDomy7Gm09rovuVWmKa_ISB0WbHhhtfCMC5bWredJUK2sheayZ5R03TsCD3f6hbH39fFhRpdMjAM2kNYJyVESyjrJuDpFmjKaimCVavoRh03ihI1ha6mndXf0Avj6U56fVOi2eN3KZf-s11fJ6MHG0tSLu1houW1pKTAzrawOzfA5n9T1fsP14t_TFRbtksZfu7ZOn5TrWCiUZ_fXajuC7lcvH3VKM5-A46-rL8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77601388</pqid></control><display><type>article</type><title>Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Stege, Reinhard ; Fröhlander, Nils ; Carlström, Kjell ; Pousette, Åke ; Von Schoultz, Bo</creator><creatorcontrib>Stege, Reinhard ; Fröhlander, Nils ; Carlström, Kjell ; Pousette, Åke ; Von Schoultz, Bo</creatorcontrib><description>The effects of parenteral and parenteral plus oral estrogen therapy on the serum levels of sex hormone binding globulin (SHBG), pregnancy‐associated (α‐PAG), growth hormone (GH), and somatomedin C (SmC) were studied in 26 patients with prostatic cancer. Intramuscular polyestradiol phosphate treatment, yielding a mean serum level of estradiol‐17β of 1,446 pM and a mean testosterone level of 4.5 nM, had no significant effects on α‐PAG, GH, and SmC and increased SHBG levels only marginally. Combined treatment with intramuscular polyestradiol phosphate and oral ethinyl estradiol greatly increased SHBG and α‐PAG levels and caused elevated GH and decreased SmC levels. The route of estrogen administration is probably of major importance for the hormonal effects on hepatic activity as reflected by SHBG and α2‐PAG levels. Bypassing the portal circulation might be advantageous with respect to liver‐related side effects of estrogen therapy. GH and SmC might act as mediators of estrogen effects on the human liver.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.2990100407</identifier><identifier>PMID: 2440014</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Oral ; Aged ; alpha-Macroglobulins - blood ; Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Estradiol - administration & dosage ; Estradiol - therapeutic use ; estrogen administration route ; growth hormone ; Growth Hormone - blood ; Humans ; Injections, Intramuscular ; Insulin-Like Growth Factor I - blood ; Liver - metabolism ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; pregnancy associated ; Prostatic Neoplasms - drug therapy ; sex hormone binding globulin ; Sex Hormone-Binding Globulin - analysis ; Sex Hormone-Binding Globulin - metabolism ; somatomedin C ; Somatomedins - blood ; α2-macroglobulin</subject><ispartof>The Prostate, 1987, Vol.10 (4), p.333-338</ispartof><rights>Copyright © 1987 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4117-ee3839393fc8aacad64f7c5db0e7a41354c427c34961268f07969d7a39d31c583</citedby><cites>FETCH-LOGICAL-c4117-ee3839393fc8aacad64f7c5db0e7a41354c427c34961268f07969d7a39d31c583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.2990100407$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.2990100407$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,4025,27927,27928,27929,45578,45579</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7642910$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2440014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stege, Reinhard</creatorcontrib><creatorcontrib>Fröhlander, Nils</creatorcontrib><creatorcontrib>Carlström, Kjell</creatorcontrib><creatorcontrib>Pousette, Åke</creatorcontrib><creatorcontrib>Von Schoultz, Bo</creatorcontrib><title>Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>The effects of parenteral and parenteral plus oral estrogen therapy on the serum levels of sex hormone binding globulin (SHBG), pregnancy‐associated (α‐PAG), growth hormone (GH), and somatomedin C (SmC) were studied in 26 patients with prostatic cancer. Intramuscular polyestradiol phosphate treatment, yielding a mean serum level of estradiol‐17β of 1,446 pM and a mean testosterone level of 4.5 nM, had no significant effects on α‐PAG, GH, and SmC and increased SHBG levels only marginally. Combined treatment with intramuscular polyestradiol phosphate and oral ethinyl estradiol greatly increased SHBG and α‐PAG levels and caused elevated GH and decreased SmC levels. The route of estrogen administration is probably of major importance for the hormonal effects on hepatic activity as reflected by SHBG and α2‐PAG levels. Bypassing the portal circulation might be advantageous with respect to liver‐related side effects of estrogen therapy. GH and SmC might act as mediators of estrogen effects on the human liver.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>alpha-Macroglobulins - blood</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Estradiol - administration & dosage</subject><subject>Estradiol - therapeutic use</subject><subject>estrogen administration route</subject><subject>growth hormone</subject><subject>Growth Hormone - blood</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Insulin-Like Growth Factor I - blood</subject><subject>Liver - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>pregnancy associated</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>sex hormone binding globulin</subject><subject>Sex Hormone-Binding Globulin - analysis</subject><subject>Sex Hormone-Binding Globulin - metabolism</subject><subject>somatomedin C</subject><subject>Somatomedins - blood</subject><subject>α2-macroglobulin</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUEFvFCEYJUZTt9WzJxMOxlOnhYEZBnsya201jTWuxsQLocxHF52BFVjrHv3nMu5mjSdDAnz53nvf-x5CTyg5oYTUp6sY0kktJSkVJ-IemlEiRVWK5j6akVqQilMmHqLDlL6SCUXqA3RQc14KPkO_FhlicH2VwCeX3Q_ARTKD8-kY38Zwl5d4GeIYPGDte5zCqHMYoXcez3G5JgNZZ2ew0d5AfIHPrQWTEw4Wr3QEXwbo4Q85TB9IOYZb8DgvS2O1eYQeWD0keLx7j9Cn1-cf55fV1fXFm_nLq8pwSkUFwDomy7Gm09rovuVWmKa_ISB0WbHhhtfCMC5bWredJUK2sheayZ5R03TsCD3f6hbH39fFhRpdMjAM2kNYJyVESyjrJuDpFmjKaimCVavoRh03ihI1ha6mndXf0Avj6U56fVOi2eN3KZf-s11fJ6MHG0tSLu1houW1pKTAzrawOzfA5n9T1fsP14t_TFRbtksZfu7ZOn5TrWCiUZ_fXajuC7lcvH3VKM5-A46-rL8</recordid><startdate>1987</startdate><enddate>1987</enddate><creator>Stege, Reinhard</creator><creator>Fröhlander, Nils</creator><creator>Carlström, Kjell</creator><creator>Pousette, Åke</creator><creator>Von Schoultz, Bo</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1987</creationdate><title>Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy</title><author>Stege, Reinhard ; Fröhlander, Nils ; Carlström, Kjell ; Pousette, Åke ; Von Schoultz, Bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4117-ee3839393fc8aacad64f7c5db0e7a41354c427c34961268f07969d7a39d31c583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>alpha-Macroglobulins - blood</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Estradiol - administration & dosage</topic><topic>Estradiol - therapeutic use</topic><topic>estrogen administration route</topic><topic>growth hormone</topic><topic>Growth Hormone - blood</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Insulin-Like Growth Factor I - blood</topic><topic>Liver - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>pregnancy associated</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>sex hormone binding globulin</topic><topic>Sex Hormone-Binding Globulin - analysis</topic><topic>Sex Hormone-Binding Globulin - metabolism</topic><topic>somatomedin C</topic><topic>Somatomedins - blood</topic><topic>α2-macroglobulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stege, Reinhard</creatorcontrib><creatorcontrib>Fröhlander, Nils</creatorcontrib><creatorcontrib>Carlström, Kjell</creatorcontrib><creatorcontrib>Pousette, Åke</creatorcontrib><creatorcontrib>Von Schoultz, Bo</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stege, Reinhard</au><au>Fröhlander, Nils</au><au>Carlström, Kjell</au><au>Pousette, Åke</au><au>Von Schoultz, Bo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>1987</date><risdate>1987</risdate><volume>10</volume><issue>4</issue><spage>333</spage><epage>338</epage><pages>333-338</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>The effects of parenteral and parenteral plus oral estrogen therapy on the serum levels of sex hormone binding globulin (SHBG), pregnancy‐associated (α‐PAG), growth hormone (GH), and somatomedin C (SmC) were studied in 26 patients with prostatic cancer. Intramuscular polyestradiol phosphate treatment, yielding a mean serum level of estradiol‐17β of 1,446 pM and a mean testosterone level of 4.5 nM, had no significant effects on α‐PAG, GH, and SmC and increased SHBG levels only marginally. Combined treatment with intramuscular polyestradiol phosphate and oral ethinyl estradiol greatly increased SHBG and α‐PAG levels and caused elevated GH and decreased SmC levels. The route of estrogen administration is probably of major importance for the hormonal effects on hepatic activity as reflected by SHBG and α2‐PAG levels. Bypassing the portal circulation might be advantageous with respect to liver‐related side effects of estrogen therapy. GH and SmC might act as mediators of estrogen effects on the human liver.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>2440014</pmid><doi>10.1002/pros.2990100407</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 1987, Vol.10 (4), p.333-338 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77601388 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Administration, Oral Aged alpha-Macroglobulins - blood Antineoplastic agents Biological and medical sciences Chemotherapy Estradiol - administration & dosage Estradiol - therapeutic use estrogen administration route growth hormone Growth Hormone - blood Humans Injections, Intramuscular Insulin-Like Growth Factor I - blood Liver - metabolism Male Medical sciences Middle Aged Pharmacology. Drug treatments pregnancy associated Prostatic Neoplasms - drug therapy sex hormone binding globulin Sex Hormone-Binding Globulin - analysis Sex Hormone-Binding Globulin - metabolism somatomedin C Somatomedins - blood α2-macroglobulin |
| title | Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T02%3A32%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Steroid-sensitive%20proteins,%20growth%20hormone%20and%20somatomedin%20C%20in%20prostatic%20cancer:%20Effects%20of%20parenteral%20and%20oral%20estrogen%20therapy&rft.jtitle=The%20Prostate&rft.au=Stege,%20Reinhard&rft.date=1987&rft.volume=10&rft.issue=4&rft.spage=333&rft.epage=338&rft.pages=333-338&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.2990100407&rft_dat=%3Cproquest_cross%3E77601388%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77601388&rft_id=info:pmid/2440014&rfr_iscdi=true |